Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29


Discovery at the interface: Toward novel anti-proliferative agents targeting human estrogen receptor/S100 interactions.

Lee DH, Asare BK, Rajnarayanan RV.

Cell Cycle. 2016 Oct 17;15(20):2806-18. doi: 10.1080/15384101.2016.1220460.


Predictive features of ligand-specific signaling through the estrogen receptor.

Nwachukwu JC, Srinivasan S, Zheng Y, Wang S, Min J, Dong C, Liao Z, Nowak J, Wright NJ, Houtman R, Carlson KE, Josan JS, Elemento O, Katzenellenbogen JA, Zhou HB, Nettles KW.

Mol Syst Biol. 2016 Apr 22;12(4):864. doi: 10.15252/msb.20156701.


Spatial mapping of juxtacrine axo-glial interactions identifies novel molecules in peripheral myelination.

Poitelon Y, Bogni S, Matafora V, Della-Flora Nunes G, Hurley E, Ghidinelli M, Katzenellenbogen BS, Taveggia C, Silvestri N, Bachi A, Sannino A, Wrabetz L, Feltri ML.

Nat Commun. 2015 Sep 18;6:8303. doi: 10.1038/ncomms9303.


BIG3 Inhibits the Estrogen-Dependent Nuclear Translocation of PHB2 via Multiple Karyopherin-Alpha Proteins in Breast Cancer Cells.

Kim NH, Yoshimaru T, Chen YA, Matsuo T, Komatsu M, Miyoshi Y, Tanaka E, Sasa M, Mizuguchi K, Katagiri T.

PLoS One. 2015 Jun 8;10(6):e0127707. doi: 10.1371/journal.pone.0127707. eCollection 2015.


Estradiol inhibits Th17 cell differentiation through inhibition of RORγT transcription by recruiting the ERα/REA complex to estrogen response elements of the RORγT promoter.

Chen RY, Fan YM, Zhang Q, Liu S, Li Q, Ke GL, Li C, You Z.

J Immunol. 2015 Apr 15;194(8):4019-28. doi: 10.4049/jimmunol.1400806. Epub 2015 Mar 13.


Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development.

Manavathi B, Samanthapudi VS, Gajulapalli VN.

Front Cell Dev Biol. 2014 Aug 12;2:34. doi: 10.3389/fcell.2014.00034. eCollection 2014. Review.


Selective estrogen receptor modulators: tissue specificity and clinical utility.

Martinkovich S, Shah D, Planey SL, Arnott JA.

Clin Interv Aging. 2014 Aug 28;9:1437-52. doi: 10.2147/CIA.S66690. eCollection 2014. Review.


Prohibitin is required for transcriptional repression by the WT1-BASP1 complex.

Toska E, Shandilya J, Goodfellow SJ, Medler KF, Roberts SG.

Oncogene. 2014 Oct 23;33(43):5100-8. doi: 10.1038/onc.2013.447. Epub 2013 Oct 28.


Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells.

Yoshimaru T, Komatsu M, Matsuo T, Chen YA, Murakami Y, Mizuguchi K, Mizohata E, Inoue T, Akiyama M, Yamaguchi R, Imoto S, Miyano S, Miyoshi Y, Sasa M, Nakamura Y, Katagiri T.

Nat Commun. 2013;4:2443. doi: 10.1038/ncomms3443.


The coregulator, repressor of estrogen receptor activity (REA), is a crucial regulator of the timing and magnitude of uterine decidualization.

Zhao Y, Park S, Bagchi MK, Taylor RN, Katzenellenbogen BS.

Endocrinology. 2013 Mar;154(3):1349-60. doi: 10.1210/en.2012-2026. Epub 2013 Feb 7.


The ligand-mediated nuclear mobility and interaction with estrogen-responsive elements of estrogen receptors are subtype specific.

Muyan M, Callahan LM, Huang Y, Lee AJ.

J Mol Endocrinol. 2012 Oct 30;49(3):249-66. doi: 10.1530/JME-12-0097. Print 2012 Dec.


Uterine development and fertility are dependent on gene dosage of the nuclear receptor coregulator REA.

Park S, Yoon S, Zhao Y, Park SE, Liao L, Xu J, Lydon JP, DeMayo FJ, O'Malley BW, Bagchi MK, Katzenellenbogen BS.

Endocrinology. 2012 Aug;153(8):3982-94. doi: 10.1210/en.2012-1044. Epub 2012 May 14.


Repressor of estrogen receptor activity (REA) is essential for mammary gland morphogenesis and functional activities: studies in conditional knockout mice.

Park S, Zhao Y, Yoon S, Xu J, Liao L, Lydon J, DeMayo F, O'Malley BW, Katzenellenbogen BS.

Endocrinology. 2011 Nov;152(11):4336-49. doi: 10.1210/en.2011-1100. Epub 2011 Aug 23.


Roles of prohibitin in growth control and tumor suppression in human cancers.

Wang S, Faller DV.

Transl Oncogenomics. 2008 Feb 10;3:23-37.

Free PMC Article

Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.

Karmakar S, Gao T, Pace MC, Oesterreich S, Smith CL.

Mol Endocrinol. 2010 Jun;24(6):1187-202. doi: 10.1210/me.2009-0480. Epub 2010 Apr 14.


Identification of four novel phosphorylation sites in estrogen receptor alpha: impact on receptor-dependent gene expression and phosphorylation by protein kinase CK2.

Williams CC, Basu A, El-Gharbawy A, Carrier LM, Smith CL, Rowan BG.

BMC Biochem. 2009 Dec 31;10:36. doi: 10.1186/1471-2091-10-36.


RIP140 in thyroid hormone-repression and chromatin remodeling of Crabp1 gene during adipocyte differentiation.

Park SW, Huang WH, Persaud SD, Wei LN.

Nucleic Acids Res. 2009 Nov;37(21):7085-94. doi: 10.1093/nar/gkp780. Epub .


Liganded RARalpha and RARgamma interact with but are repressed by TNIP1.

Gurevich I, Aneskievich BJ.

Biochem Biophys Res Commun. 2009 Nov 20;389(3):409-14. doi: 10.1016/j.bbrc.2009.08.159. Epub 2009 Sep 2.


Potential of selective estrogen receptor modulators as treatments and preventives of breast cancer.

Peng J, Sengupta S, Jordan VC.

Anticancer Agents Med Chem. 2009 Jun;9(5):481-99. Review.


Estradiol downregulation of the tumor suppressor gene BTG2 requires estrogen receptor-alpha and the REA corepressor.

Karmakar S, Foster EA, Smith CL.

Int J Cancer. 2009 Apr 15;124(8):1841-51. doi: 10.1002/ijc.24133.

Items per page

Supplemental Content

Support Center